Cellular Dynamics International Launches Opsis Therapeutics to Develop Cell Therapies for Treatment of Retinal Diseases

Cellular Dynamics International Launches Opsis Therapeutics to Develop Cell Therapies for Treatment of Retinal Diseases

MADISON, WIS – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. The Opsis Therapeutics team brings deep expertise and a track record of developing breakthrough technologies and building next-generation cell therapeutic programs. The venture has been founded in partnership with David Gamm, M.D., Ph.D., a world leader and pioneer in the differentiation and transplantation of iPSC-derived retinal cells.

“Acquired and inherited diseases of the retina, such as age-related macular degeneration and retinitis pigmentosa, afflict tens of millions of people worldwide,” said Dr. Ga

< | >